



Alert Summary for Week of January 3 – 7

January 7, 2022

01/03/22

- [Pharmacy Claims Denial Issue](#): Medi-Cal Rx has identified a Pharmacy claims denial related to beneficiary eligibility and is working to resolve the problem.

01/05/22

- [Reject Code Suspension](#): Medi-Cal Rx is temporarily suspending Reject Code 16 M/I Prescription/Service Reference Number.

01/06/22

- [Billing Guidance for Pharmacy Providers on COVID-19 Oral Antivirals](#): The Department of Health Care Services (DHCS) is providing the following guidance for pharmacy providers regarding the billing of self-administered free COVID-19 oral antiviral drugs, Paxlovid and Molnupiravir.
- [Requirements for Medi-Cal Rx Claims](#): Describes important changes to billing prescriptions for Medi-Cal Rx beneficiaries.

01/07/22

- [Drug Utilization Review \(DUR\) Reject Codes 88 & 76](#): Medi-Cal Rx has identified a large volume of pharmacy claims denials related to Drug Utilization Review (DUR). Please review if you are a pharmacy provider whose claim was denied with a Reject Code 88 (DUR Reject Error) or, specifically for opioid claims, a Reject Code 76 (Plan Limitations Exceeded).